Nov. 6 at 7:08 PM
LifeVantage Corporation reported ongoing EPS of
$0.18, up 20% YoY, beating internal forecasts but slightly below consensus. Adjusting for an unusually low tax rate, normalized EPS would have been
$0.14, modestly under expectations.
🔹 Sales: Up 0.7% YoY to
$47.6M, missing estimates due to timing effects around the LoveBiome acquisition and a pause in consultant activity.
🔹 Margins: EBITDA declined 11% to
$3.9M with an 8.2% margin, reflecting higher shipping and warehouse costs, partly offset by lower SG&A.
🔹 Outlook: Management reaffirmed FY26 guidance — sales of
$225–240M, adjusted EBITDA of
$23–26M, and EPS of
$1.00–1.15.
🔹 Growth Drivers: Integration of LoveBiome and expansion of the
Check out Doug Lane's full report for more!
https://www.watertowerresearch.com/doc?docID=UR_LFVN_11062025
#LifeVantage
$LFVN #EarningsUpdate #GutHealth #LoveBiome #GLP1 #MindBody #Wellness #Nutrigenomics #DirectSelling #SmallCapStocks
